Key result
Aggressive treatment for primary hepatic angiosarcoma yielded a mean survival time of 233.1 days versus 146.5 days for nonaggressive treatment, with no significant difference between groups (P=0.3256).
Why the study?
Primary hepatic angiosarcoma is a rare and aggressive tumor, and the standard therapeutic care remains unclear.
Does aggressive treatment improve survival time compared to nonaggressive treatment in patients with primary hepatic angiosarcoma?
Cohort (n=19)
No
Does aggressive treatment improve survival time compared to nonaggressive treatment in patients with primary hepatic angiosarcoma?
Absolute Event Rate: 233.1% vs 146.5%
p-value: p=0.3256
In a small retrospective cohort of patients with primary hepatic angiosarcoma, aggressive treatment did not significantly improve survival time compared to nonaggressive treatment.
Resection may extend survival in resectable PHA; leaves open transplant contraindication and systemic therapy optimization in prospective studies.
Background and Aims: Of all primary liver tumors, primary hepatic angiosarcoma (PHA) is a rare and aggressive malignant vascular tumor. The standard therapeutic care for hepatic angiosarcoma remains unclear. This study compared the survival outcomes of aggressive treatment (resection and liver transplant) and nonaggressive treatment (chemotherapy, transarterial chemoembolization [TACE], and conservative treatments) for patients with PHA and analyzed the prognostic factors influencing survival. Materials and Methods: Data of patients diagnosed as having PHA at our facility were retrospectively reviewed. The primary outcome was survival time. The secondary outcome was calculated baseline characteristics. Results: We included a total of 19 patients, who were divided into 2 treatment groups: aggressive (8 patients had undergone resection or transplants) and nonaggressive (11 patients had undergone TACE, chemotherapy, or conservative treatment). The mean survival time was 233.1 ± 189.7 days in the aggressive treatment group and 146.5 ± 115.8 days in the nonaggressive treatment group. A Kaplan-Meier plot revealed no significant difference in survival time between the 2 treatment groups (P = .3256). Conclusions: The survival time of patients receiving aggressive treatment was longer than that of those receiving nonaggressive treatment. The long term survival time in some selective cases of aggressive treatment will be achieved. Thought a difference was not significant between the groups. Because the number of patients was limited, more cases are required to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) conducted a cohort in Primary hepatic angiosarcoma (PHA) (n=19). Aggressive treatment (resection and liver transplant) vs. Nonaggressive treatment (chemotherapy, TACE, and conservative treatments) was evaluated on Survival time (p=0.3256). Aggressive treatment for primary hepatic angiosarcoma yielded a mean survival time of 233.1 days versus 146.5 days for nonaggressive treatment, with no significant difference between groups (P=0.3256).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: